Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12559MR)

This product GTTS-WQ12559MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets Canlupfam NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12559MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13309MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ4364MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ5582MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7766
GTTS-WQ11819MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ8779MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ10727MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ982MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ6852MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW